| Inhibition of dual-specificity tyrosine phosphorylation-regulated kinase 2 perturbs 26S proteasome-addicted neoplastic progression S Banerjee, T Wei, J Wang, JJ Lee, HL Gutierrez, O Chapman, SE Wiley, ... Proceedings of the National Academy of Sciences 116 (49), 24881-24891, 2019 | 47 | 2019 |
| Emerging roles of DYRK2 in cancer V Tandon, L de la Vega, S Banerjee Journal of Biological Chemistry 296, 2021 | 44 | 2021 |
| Synthesis of N-(4-chlorophenyl) substituted pyrano[2,3-c]pyrazoles enabling PKBβ/AKT2 inhibitory and in vitro anti-glioma activity RM Vala, V Tandon, LG Nicely, L Guo, Y Gu, S Banerjee, HM Patel Annals of Medicine 54 (1), 2548-2560, 2022 | 20* | 2022 |
| Syrbactin-class dual constitutive- and immuno-proteasome inhibitor TIR-199 impedes myeloma-mediated bone degeneration in vivo V Tandon, RM Vala, A Chen, RL Sah, HM Patel, MC Pirrung, S Banerjee Bioscience Reports 42 (2), BSR20212721, 2022 | 14 | 2022 |
| Dual inhibition of HSF1 and DYRK2 impedes cancer progression V Tandon, R Moreno, K Allmeroth, J Quinn, SE Wiley, LG Nicely, ... Bioscience reports 43 (1), BSR20222102, 2023 | 5 | 2023 |
| Ca2+-dependent liquid-liquid phase separation underlies intracellular Ca2+ stores JE Mayfield, AJ Pollak, CA Worby, JC Xu, V Tandon, AC Newton, ... bioRxiv, 2021.07. 06.451223, 2021 | 4 | 2021 |
| AI is a viable alternative to high throughput screening: a 318-target study Scientific reports 14 (1), 7526, 2024 | 2 | 2024 |
